Update on caprolactam exchange meeting (Nov 5)

On November 5, 2025, an industry exchange meeting for the caprolactam sector was held. Centering on the spirit of the announcement jointly issued by the National Development and Reform Commission (NDRC) and the State Administration for Market Regulation (SAMR) regarding regulating disorderly price competition and safeguarding a sound market order, the core agenda focused on discussions about industry "anti-involution" measures, with a final proposal to cut production by 20% across the entire industry.

According to tracking and statistics from CCFGroup, multiple key enterprises in the sector have implemented or are advancing production cuts, including Baling Hengyi, Pingmei Shenma, Lunan Chemical, Risun Group, Hualu Hengsheng, and Eversun Jinjiang. As industry consensus deepens, it is expected that other enterprises will also gradually implement the cuts in accordance with unified arrangements.

This production reduction initiative is a crucial step in practicing industry self-regulation and resisting vicious competition. It will not only effectively safeguard a fair competitive market environment and protect the legitimate rights and interests of enterprises in the sector but also help the caprolactam industry break free from the predicament of disorderly competition, achieve optimal resource allocation, and lay a solid foundation for the long-term, healthy, and sustainable development of the entire industry.